Company Directories & Business Directories
JOURNAL AND COURIER
Company Name: Corporate Name:
JOURNAL AND COURIER
Company Title:
Company Description:
Keywords to Search:
Company Address:
3041 Plantation Drive,YORKTOWN,IN,USA
ZIP Code: Postal Code:
47885
Telephone Number:
7657422410 (+1-765-742-2410)
Fax Number:
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):
731304
USA SIC Description:
Media Brokers
Number of Employees:
Sales Amount:
Credit History:
Credit Report:
Contact Person:
Remove my name
copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example , Blogger Example )
copy to clipboard
Company News:
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
The New England Journal of Medicine | Research Review Articles on . . . The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Current Issue | New England Journal of Medicine Explore the current issue of The New England Journal of Medicine (Vol 393 No 21)
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP
Highly Pathogenic Avian Influenza A(H5N1) Virus Infections in Humans Highly pathogenic avian influenza A(H5N1) viruses have caused widespread infections in dairy cows and poultry in the United States, with sporadic human cases We describe characteristics of human A
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual Current disease-modifying therapies for multiple sclero
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung . . . Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3